Partners

AVIPEP Therapeutics is a next-generation ADC company developing a pipeline
of AvDCs (Avibody Drug Conjugates) with a focus on improved tumor targeting
to deliver best-in-class clinical results and to better fight relapsed/refractory
disease. Privately-held and based in Cambridge MA and Melbourne VIC, AVIPEP
is eager to discuss co-development, asset out-licensing or investment. Our
proprietary Avibody™ platform will improve targeting and tolerability in all
manner of next-gen ADCs.

Website: www.avipep.com

Pipeline Innovation Partner

CytomX Therapeutics leverages its industry-leading PROBODY® conditional activation masking technology to pioneer a novel class of biologics and develop a multi-modality clinical pipeline including ADCs.

CX-2051, being studied in Phase 1, is a conditionally activated ADC directed toward EpCAM, a validated target with a narrow therapeutic index in conventional antibody approaches.

The Probody® platform is intended to unlock EpCAM as an ADC target and demonstrate the potential to significantly expand the ADC target landscape.

Website: www.cytomx.com

Pipeline Innovation Partner

Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop innovative therapies to target high unmet medical needs in oncology and infection diseases. We establish partnerships with academic, biotech, and pharmaceutical institutions to bridge the gap between disruptive discovery products and international patient reach. Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential including a CD37-targeted ADC for AML/MDS (Debio 1562M) and a HER3-targeted ADC in solid tumors (Debio 0532).

Website: www.debiopharm.com

PIPELINE INNOVATION PARTNER

PINOTBIO develops novel treatments for patients resistant to existing therapies, focusing on antibody-drug conjugates (ADC). Utilizing robust R&D, we created the PINOT-ADC™ platform independently.

Our PINOT-payload, a unique Top1 inhibitor, offers dual mechanisms of action, while the PINOT-linker reduces normal tissue absorption and toxicity risks, common challenges in ADC development. Collaborating with partners, we leverage PINOT-ADC™ technology to advance new ADC-based anticancer treatments.

Website: www.pinotbio.com

PIPELINE INNOVATION PARTNER

Shasqi’s mission is to transform cancer treatment using click chemistry (Nobel-Prize winning technology) in humans.
Our Click Activated Protodrugs Against Cancer (CAPAC) approach separates tumor antigen binders from payloads, reuniting them at the tumor via click chemistry. This enables oncology therapies to be present only where they are needed, maximizing efficacy by minimizing efficacy-limiting toxicities.
CAPAC is clinically validated and we are advancing novel ADC & RLT therapies based on validated and new antigen targets.

Website: www.shasqi.com

View Agenda

Buy Ticket

To the top

Partners

VENUE

LOCATION

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH